Experimental cell therapy takes on Drug-Resistant melanoma
Disease control
Not yet recruiting
This Phase 2 trial tests a new cell therapy called RAPA-201 for people with advanced melanoma that has stopped responding to PD-(L)1 inhibitors. The therapy uses a patient's own immune cells, modified to resist the drug rapamycin, and is given along with chemotherapy. The study a…
Phase: PHASE2 • Sponsor: Rapa Therapeutics LLC • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC